Literature DB >> 27334757

Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells.

Quan Zeng1, Zhihai Wang1, Chuan Liu1, Zhitao Gong1, Li Yang1, Liang Jiang1, Zuxia Ma1, Yi Qian1, Yucheng Yang1, Houyong Kang1, Suling Hong1, Youquan Bu2, Guohua Hu3.   

Abstract

Nasopharyngeal carcinoma (NPC) is a rare but highly invasive cancer that is prevalent among people of southern Chinese ancestry in southern China and Southeast Asia. Radiotherapy and cisplatin (CDDP)-based chemotherapy are the main treatment options. Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with NPC, and many cases are resistant to CDDP and radiotherapy. NFBD1 functions in cell cycle checkpoint activation and DNA repair following DNA damage. In this study, we identified the NFBD1 as a tractable molecular target to chemosensitize NPC cells. NFBD1 expression in NPC CNE1 cell lines was depleted using lentivirus-mediated short hairpin RNA, and the elevated sensitivity of these NFBD1-inhibited NPC cells to therapeutic reagent CDDP and 5-fluorouracil (5-FU) was evaluated using MTS assays. Flow cytometry analysis also showed that NFBD1 knockdown led to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells. Furthermore, we implicated the involvement of NFBD1 in Rad51 and DNA-PKcs foci formation following CDDP or 5-FU chemotherapy. In conclusion, NFBD1 knockdown improves the chemosensitivity of NPC cells by inhibiting cell growth and promoting apoptosis through the impairment of DNA damage repair, suggesting NFBD1 as a novel therapeutic target for NPC.

Entities:  

Keywords:  Apoptosis; Chemosensitivity; DNA damage response; DNA double-strand breaks; NFBD1/MDC1; NPC

Mesh:

Substances:

Year:  2016        PMID: 27334757     DOI: 10.1007/s11010-016-2739-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  52 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

2.  MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals.

Authors:  Zhenkun Lou; Katherine Minter-Dykhouse; Sonia Franco; Monica Gostissa; Melissa A Rivera; Arkady Celeste; John P Manis; Jan van Deursen; André Nussenzweig; Tanya T Paull; Frederick W Alt; Junjie Chen
Journal:  Mol Cell       Date:  2006-01-20       Impact factor: 17.970

3.  Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage.

Authors:  Hiroki Shima; Hidekazu Suzuki; Jiying Sun; Kazuteru Kono; Lin Shi; Aiko Kinomura; Yasunori Horikoshi; Tsuyoshi Ikura; Masae Ikura; Roland Kanaar; Kazuhiko Igarashi; Hisato Saitoh; Hitoshi Kurumizaka; Satoshi Tashiro
Journal:  J Cell Sci       Date:  2013-09-17       Impact factor: 5.285

Review 4.  Treatment for metastatic nasopharyngeal carcinoma.

Authors:  Y Bensouda; W Kaikani; N Ahbeddou; R Rahhali; M Jabri; H Mrabti; H Boussen; H Errihani
Journal:  Eur Ann Otorhinolaryngol Head Neck Dis       Date:  2010-12-21       Impact factor: 2.080

5.  NFBD1/KIAA0170 is a novel nuclear transcriptional transactivator with BRCT domain.

Authors:  T Ozaki; T Nagase; S Ichimiya; N Seki; M Ohiri; N Nomura; N Takada; S Sakiyama; B L Weber; A Nakagawara
Journal:  DNA Cell Biol       Date:  2000-08       Impact factor: 3.311

6.  Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.

Authors:  Z Ping Lin; Yashang Lee; Fang Lin; Michael F Belcourt; Peining Li; Joseph G Cory; Peter M Glazer; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2011-08-29       Impact factor: 4.436

7.  MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways.

Authors:  Zhenkun Lou; Katherine Minter-Dykhouse; Xianglin Wu; Junjie Chen
Journal:  Nature       Date:  2003-02-27       Impact factor: 49.962

8.  DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.

Authors:  Adam Kashishian; Heather Douangpanya; Darcey Clark; Stephen T Schlachter; C Todd Eary; Justin G Schiro; Hongmei Huang; Larry E Burgess; Edward A Kesicki; James Halbrook
Journal:  Mol Cancer Ther       Date:  2003-12       Impact factor: 6.261

Review 9.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

10.  Functional and molecular defects of hiPSC-derived neurons from patients with ATM deficiency.

Authors:  L Carlessi; E Fusar Poli; G Bechi; M Mantegazza; B Pascucci; L Narciso; E Dogliotti; C Sala; C Verpelli; D Lecis; D Delia
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

View more
  9 in total

1.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal:  Cell Cycle       Date:  2017-04-05       Impact factor: 4.534

2.  NFBD1/MDC1 participates in the regulation of proliferation and apoptosis in human laryngeal squamous cell carcinoma.

Authors:  X Liu; Z Qiu; Z Wang; W Zuo; Z Gong; C Liu; Q Zeng; Y Qian; L Jiang; Y Li; Y Bu; G Hu
Journal:  Clin Transl Oncol       Date:  2017-09-18       Impact factor: 3.405

3.  AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG/miR-22-3p.

Authors:  Jinjiang Chou; Markus Kaller; Stephanie Jaeckel; Matjaz Rokavec; Heiko Hermeking
Journal:  Mol Cancer       Date:  2022-05-27       Impact factor: 41.444

Review 4.  Roles for MDC1 in cancer development and treatment.

Authors:  Sophie E Ruff; Susan K Logan; Michael J Garabedian; Tony T Huang
Journal:  DNA Repair (Amst)       Date:  2020-08-11

Review 5.  Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.

Authors:  Ya Cao; Longlong Xie; Feng Shi; Min Tang; Yueshuo Li; Jianmin Hu; Lin Zhao; Luqing Zhao; Xinfang Yu; Xiangjian Luo; Weihua Liao; Ann M Bode
Journal:  Signal Transduct Target Ther       Date:  2021-01-12

6.  Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.

Authors:  Zhihai Wang; Wenqi Zuo; Quan Zeng; Yi Qian; Yanshi Li; Chuan Liu; Jue Wang; Shixun Zhong; Youquan Bu; Guohua Hu
Journal:  J Biomed Sci       Date:  2019-02-04       Impact factor: 8.410

7.  Depletion of NFBD1/MDC1 Induces Apoptosis in Nasopharyngeal Carcinoma Cells Through the p53-ROS-Mitochondrial Pathway.

Authors:  Zhihai Wang; Kui Liao; Wenqi Zuo; Xueliang Liu; Zhili Qiu; Zhitao Gong; Chuan Liu; Quan Zeng; Yi Qian; Liang Jiang; Youquan Bu; Suling Hong; Guohua Hu
Journal:  Oncol Res       Date:  2017-01-02       Impact factor: 5.574

8.  ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma.

Authors:  Bo Zhang; Bomiao Cui; Jintao Du; Xin Shen; Kun Wang; Jiao Chen; Liying Xiao; Chongkui Sun; Yan Li
Journal:  Cancer Manag Res       Date:  2019-01-09       Impact factor: 3.989

9.  The Homologous Recombination Repair Pathway is Associated with Resistance to Radiotherapy in Nasopharyngeal Carcinoma.

Authors:  Zhihai Wang; Wenqi Zuo; Quan Zeng; Yanshi Li; Tao Lu; Youquan Bu; Guohua Hu
Journal:  Int J Biol Sci       Date:  2020-01-01       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.